135 related articles for article (PubMed ID: 17118783)
1. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.
Jaglowski SM; Alinari L; Lapalombella R; Muthusamy N; Byrd JC
Blood; 2010 Nov; 116(19):3705-14. PubMed ID: 20610811
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in Chronic Lymphocytic Leukaemia (CLL).
Freeman CL; Gribben JG
Curr Hematol Malig Rep; 2016 Feb; 11(1):29-36. PubMed ID: 26857283
[TBL] [Abstract][Full Text] [Related]
3. CD44v6: a target for antibody-based cancer therapy.
Heider KH; Kuthan H; Stehle G; Munzert G
Cancer Immunol Immunother; 2004 Jul; 53(7):567-79. PubMed ID: 14762695
[TBL] [Abstract][Full Text] [Related]
4. Adverse Renal Effects of Anticancer Immunotherapy: A Review.
Borówka M; Łącki-Zynzeling S; Nicze M; Kozak S; Chudek J
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077623
[TBL] [Abstract][Full Text] [Related]
5. CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation.
Shafiei-Jahani P; Helou DG; Hurrell BP; Galle-Treger L; Howard E; Quach C; Painter JD; Fung M; Lo R; Allayee H; Akbari O
Mucosal Immunol; 2021 Jul; 14(4):899-911. PubMed ID: 33731828
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.
Li Z; Richards S; Surks HK; Jacobs A; Panzara MA
Clin Exp Immunol; 2018 Dec; 194(3):295-314. PubMed ID: 30144037
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab-induced elimination of HIV-1-infected immune cells.
Ruxrungtham K; Sirivichayakul S; Buranapraditkun S; Krause W
J Virus Erad; 2016 Jan; 2(1):12-8. PubMed ID: 27482429
[TBL] [Abstract][Full Text] [Related]
8. Differential gene expression profiles of PPP2R5C-siRNA-treated malignant T cells.
Chen Y; Liu S; Shen Q; Zha X; Zheng H; Yang L; Chen S; Wu X; Li B; Li Y
DNA Cell Biol; 2013 Oct; 32(10):573-81. PubMed ID: 23941244
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.
Treon SP; Soumerai JD; Hunter ZR; Patterson CJ; Ioakimidis L; Kahl B; Boxer M
Blood; 2011 Jul; 118(2):276-81. PubMed ID: 21566092
[TBL] [Abstract][Full Text] [Related]
10. Adoptive T-cell therapy for B-cell malignancies.
Hudecek M; Anderson LD; Nishida T; Riddell SR
Expert Rev Hematol; 2009 Oct; 2(5):517-32. PubMed ID: 21083018
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
Berger JR; Houff SA; Major EO
MAbs; 2009; 1(6):583-9. PubMed ID: 20073129
[TBL] [Abstract][Full Text] [Related]
12. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
Alatrash G; Albitar M; O'Brien S; Wang X; Manshouri T; Faderl S; Ferrajoli A; Burger J; Garcia-Manero G; Kantarjian HM; Lerner S; Keating MJ; Wierda WG
Br J Haematol; 2010 Feb; 148(3):386-93. PubMed ID: 19895616
[TBL] [Abstract][Full Text] [Related]
13. Receptor-directed therapy of T-cell leukemias and lymphomas.
Morris JC; Waldmann TA; Janik JE
J Immunotoxicol; 2008 Apr; 5(2):235-48. PubMed ID: 18569395
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab in CLL and other lymphoid neoplasms.
Ravandi F; O'brien S
Cancer Invest; 2006 Nov; 24(7):718-25. PubMed ID: 17118783
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab.
Ravandi F; O'Brien S
Expert Rev Anticancer Ther; 2005 Feb; 5(1):39-51. PubMed ID: 15757437
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
Boyd K; Dearden CE
Expert Rev Anticancer Ther; 2008 Apr; 8(4):525-33. PubMed ID: 18402519
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
[TBL] [Abstract][Full Text] [Related]
18. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
Dumont FJ
Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
